$RHHBY

Global pregnancy detection kits market projected to grow 41% from $1.91B (2025) to $2.69B (2031) amid tech advances, but faces accuracy and trust challenges.

Roche to acquire digital pathology company PathAI for up to $1.05 billion, paying $750 million upfront with $300 million in milestone payments to strengthen AI diagnostics capabilities.

Zealand Pharma reports strong Q1 2026 results with obesity treatment advances, $700M collaboration revenue, and $200M share buyback program.

Roche to acquire digital pathology company PathAI for $750M upfront plus $300M in milestones, strengthening AI-driven diagnostic capabilities and precision medicine strategy.

Global DNA microarray market projected to grow from $2.5B in 2025 to $4.7B by 2034 at 7% CAGR, driven by genomic research and personalized medicine demand.

ABLi Therapeutics appoints Dr. Rachelle Doody, Roche neurology veteran, to board as company advances risvodetinib into Phase 3 trials for Parkinson's and related diseases.

Over 50 drugmakers advance 55+ hemophilia treatments as Novo Nordisk and competitors pursue gene therapies and next-gen factors.

Global targeted DNA-RNA sequencing market to surge from $8.6B in 2025 to $46.9B by 2035, driven by precision medicine adoption and government genomic initiatives.

Roche offers defensive 2026 portfolio appeal with 7% sales growth and 13% profit growth, emphasizing stability over explosive expansion through diversified healthcare exposure.

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.

Metagenomics sequencing market projected to grow from $2.5B (2025) to $7.5B (2034) at 13% CAGR, driven by declining sequencing costs and clinical adoption.

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

Omics clinical trials market grows 8.8% annually from $31.71B in 2025 to $47.78B by 2030, driven by personalized medicine demand and AI advances.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Global oncolytic virus immunotherapy market projected to exceed $5 billion by 2031, driven by three approved therapies and 150+ clinical candidates advancing combination approaches.

China's diabetes device market projected to nearly double from $7.19B in 2025 to $14.51B by 2034, driven by 118M patients and healthcare reforms.

Roche receives CE mark for Elecsys NfL blood test detecting neuroinflammation in relapsing-remitting multiple sclerosis, offering minimally invasive alternative to MRI monitoring.

Global NGS market projected to reach $29.5B by 2030 from $14.9B in 2025, with Asia-Pacific experiencing fastest growth driven by precision medicine adoption.

SLE drug market projected to grow nearly 150% to $5.9B by 2034 on new therapies, but biosimilar competition and pricing pressure could limit upside.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.